가상 임상시험 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 시험 디자인별, 적응증별, 단계별, 규제 이온별, 경쟁별(2020-2030년)

Virtual Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Study Design, By Indication, By Phase, By Reg ion and Competition, 2020-2030F

US $ 4,500 ￦ 6,462,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,899,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,489,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

가상 임상시험 세계 시장 규모는 2024년 84억 8,000만 달러, 2030년까지 157억 6,000만 달러에 달할 것으로 예상되며, 10.86%의 CAGR로 성장할 것으로 예상됩니다. 분산형 또는 원격 임상시험이라고도 불리는 가상 임상시험(VCTs)은 원격 등록, 모니터링, 데이터 수집에 디지털 도구를 활용함으로써 임상 연구 방식에 혁명을 일으키고 있습니다. 이러한 임상시험은 환자 접근성을 개선하고, 실시간 데이터 수집을 강화하며, 임상시험 운영을 간소화합니다. VCT의 채택은 기술 발전, 환자 중심 임상시험 모델 추진, 효율적이고 유연한 임상시험 설계의 필요성에 의해 추진되고 있습니다. VCT는 현장 방문의 필요성을 제거함으로써 참여 장벽을 낮추고 임상시험의 포괄성을 향상시킵니다. 데이터 프라이버시와 규제의 복잡성에도 불구하고, 가상 모델은 기존 임상시험의 한계에 대한 지속가능한 솔루션으로 각광받고 있으며, 세계 연구 이니셔티브의 확장성과 운영 효율성을 향상시키고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	84억 8,000만 달러
시장 규모 : 2030년	157억 6,000만 달러
CAGR : 2025-2030년	10.86%
급성장 부문	종양학
최대 시장	북미

주요 시장 촉진요인

질병 부담 증가

주요 시장 과제

데이터 보안 및 프라이버시

주요 시장 동향

원격 모니터링 및 웨어러블

목차

제1장 서비스 개요

• 시장 정의
• 시장 범위
  • 대상 시장
  • 조사 대상 연도
  • 주요 시장 세분화

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 가상 임상시험 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 시험 디자인별(개입 연구, 관찰 연구, 접근성 확대 연구)
  • 적응증별(종양학, 심혈관질환, 기타)
  • 단계별(단계 1, 단계 2, 단계 3, 단계 4)
  • 기업별(2024년)
  • 지역별
• 시장 맵

제6장 북미의 가상 임상시험 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 가상 임상시험 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 가상 임상시험 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 가상 임상시험 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 가상 임상시험 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병

제13장 PESTEL 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제15장 경쟁 구도

• Medable, Inc.
• ICON, plc
• Parexel International Corporation
• Medidata Solutions Inc
• Oracle Corp
• Signant Health
• Leo Laboratories Ltd
• IQVIA Inc
• PRA Health Sciences Inc
• Clinical Ink Inc

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

ksm

영문 목차

영문목차

The Global Virtual Clinical Trials Market was valued at USD 8.48 billion in 2024 and is projected to reach USD 15.76 billion by 2030, expanding at a CAGR of 10.86%. Virtual clinical trials (VCTs), also referred to as decentralized or remote trials, are revolutionizing the clinical research process by leveraging digital tools for remote enrollment, monitoring, and data collection. These trials improve patient accessibility, enhance real-time data capture, and streamline study operations. The adoption of VCTs is being driven by technological advancements, the push for patient-centric trial models, and the need for efficient, flexible study designs. By eliminating the requirement for physical site visits, VCTs reduce barriers to participation and improve trial inclusivity. Despite challenges around data privacy and regulatory complexities, the virtual model is gaining traction as a sustainable solution to traditional trial limitations, offering enhanced scalability and operational efficiency across global research initiatives.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 8.48 Billion
Market Size 2030	USD 15.76 Billion
CAGR 2025-2030	10.86%
Fastest Growing Segment	Oncology
Largest Market	North America

Key Market Drivers

Growing Burden of Diseases

The rising incidence of chronic and rare diseases worldwide is a major driver fueling the adoption of Virtual Clinical Trials (VCTs). In 2024, over 828 million adults were reported to have diabetes, with nearly half of them untreated, indicating an urgent demand for more efficient research methodologies. Additionally, around 300 million people globally suffer from rare diseases. Traditional clinical trial models often encounter challenges like delayed recruitment and participant dropout, which can hinder medical advancements. VCTs offer a solution by using digital tools to reach broader and more diverse populations, thereby improving trial inclusivity and data relevance. The remote nature of VCTs is particularly advantageous for rare disease research, as these conditions often involve small, geographically dispersed patient groups. VCTs also expedite data collection and allow for real-time monitoring, enabling faster decision-making and adaptive trial protocols. To fully capitalize on these benefits, collaboration among stakeholders is necessary to maintain scientific rigor and regulatory compliance while improving access and outcomes.

Key Market Challenges

Data Security and Privacy

Data security and privacy are key concerns in the Virtual Clinical Trials (VCTs) market due to the extensive use of digital platforms for collecting and managing sensitive health information. The remote and tech-driven model of VCTs introduces heightened risks related to data breaches, unauthorized access, and the potential exposure of personally identifiable health data. Compliance with data protection regulations such as GDPR and HIPAA is particularly complex in multi-regional trials with varied regulatory landscapes. Addressing these issues requires robust encryption standards, secure communication protocols, and multi-factor authentication systems to protect patient data. Informed consent must be transparent and comprehensive, clearly outlining data usage and protection measures. Partnerships between technology providers, regulatory bodies, and cybersecurity experts are essential for establishing reliable frameworks that uphold data integrity and patient trust. Without strong safeguards, breaches can undermine the credibility of VCTs and stall their broader adoption.

Key Market Trends

Remote Monitoring and Wearables

The integration of remote monitoring and wearable devices is a transformative trend reshaping the Virtual Clinical Trials (VCTs) landscape. Wearables such as smartwatches and fitness trackers facilitate continuous, real-time health monitoring in everyday settings, offering rich datasets on parameters like heart rate, activity levels, and sleep patterns. This capability reduces the need for frequent site visits while improving trial accuracy through the collection of objective data. The ability to detect early signs of adverse reactions enhances patient safety and allows for proactive interventions. Additionally, remote monitoring promotes patient engagement by empowering individuals to take an active role in their health journey, which can boost trial adherence. The real-world insights gathered through these devices provide a more holistic view of treatment efficacy and patient experience. However, issues such as data integration, device interoperability, and accuracy must be addressed. Despite these hurdles, wearable-enabled monitoring is enhancing the depth and relevance of clinical trial data, contributing to more effective and efficient studies.

Key Market Players

• Medable, Inc.
• ICON, plc
• Parexel International Corporation
• Medidata Solutions Inc
• Oracle Corp
• Signant Health
• Leo Laboratories Ltd
• IQVIA Inc
• PRA Health Sciences Inc
• Clinical Ink Inc

Report Scope:

In this report, the Global Virtual Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Virtual Clinical Trials Market, By Study Design:

• Interventional
• Observational
• Expanded Access

Virtual Clinical Trials Market, By Indication:

• Oncology
• Cardiovascular Disease
• Others

Virtual Clinical Trials Market, By Phase:

• Phase 1
• Phase 2
• Phase 3
• Phase 4

Virtual Clinical Trials Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Virtual Clinical Trials Market.

Available Customizations:

Global Virtual Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customers

5. Global Virtual Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Study Design (Interventional, Observational, Expanded Access)
  • 5.2.2. By Indication (Oncology, Cardiovascular Disease, Others)
  • 5.2.3. By Phase (Phase 1, Phase 2, Phase 3, Phase 4)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Virtual Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Study Design
  • 6.2.2. By Indication
  • 6.2.3. By Phase
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Virtual Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Study Design
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Phase
  • 6.3.2. Mexico Virtual Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Study Design
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Phase
  • 6.3.3. Canada Virtual Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Study Design
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Phase

7. Europe Virtual Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Study Design
  • 7.2.2. By Indication
  • 7.2.3. By Phase
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Virtual Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Study Design
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Phase
  • 7.3.2. Germany Virtual Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Study Design
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Phase
  • 7.3.3. United Kingdom Virtual Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Study Design
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Phase
  • 7.3.4. Italy Virtual Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Study Design
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Phase
  • 7.3.5. Spain Virtual Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Study Design
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Phase

8. Asia-Pacific Virtual Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Study Design
  • 8.2.2. By Indication
  • 8.2.3. By Phase
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Virtual Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Study Design
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Phase
  • 8.3.2. India Virtual Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Study Design
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Phase
  • 8.3.3. South Korea Virtual Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Study Design
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Phase
  • 8.3.4. Japan Virtual Clinical Trials Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Study Design
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Phase
  • 8.3.5. Australia Virtual Clinical Trials Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Study Design
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Phase

9. South America Virtual Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Study Design
  • 9.2.2. By Indication
  • 9.2.3. By Phase
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Virtual Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Study Design
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Phase
  • 9.3.2. Argentina Virtual Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Study Design
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Phase
  • 9.3.3. Colombia Virtual Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Study Design
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Phase

10. Middle East and Africa Virtual Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Study Design
  • 10.2.2. By Indication
  • 10.2.3. By Phase
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Virtual Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Study Design
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Phase
  • 10.3.2. Saudi Arabia Virtual Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Study Design
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Phase
  • 10.3.3. UAE Virtual Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value & Volume
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Study Design
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Phase

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Medable, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. ICON, plc
• 15.3. Parexel International Corporation
• 15.4. Medidata Solutions Inc
• 15.5. Oracle Corp
• 15.6. Signant Health
• 15.7. Leo Laboratories Ltd
• 15.8. IQVIA Inc
• 15.9. PRA Health Sciences Inc
• 15.10. Clinical Ink Inc

16. Strategic Recommendations

17. About Us & Disclaimer

관련자료